FactorPad
Build a Better Process

Stock Risk Measures for Intellia Therapeutics Inc

A quantitative factor review as of June 30, 2021.
  1. Company Info - Description, identity and sector data.
  2. Share Data - Stock earnings and key dates.
  3. Market Risk - Beta, size, liquidity and momentum measures.
  4. Financial Risk - Earnings and dividends.
face pic by Paul Alan Davis, CFA
Updated: July 06, 2021
See how we arrive at an overall risk score of 46 for NTLA below.

/ factorpad.com / stocks / f16qgj.html


An ad-free and cookie-free website.


NTLA Risk Report

Overview

Our quantitative data points are meant to provide a high-level understanding of factors in equity risk models for Intellia Therapeutics Inc. Portfolio managers use these models to forecast risk, optimize portfolios and review performance.

We show how NTLA stock compares to 2,000+ US-based stocks, and to peers in the Manufacturing sector and Pharmaceutical Preparation Manufacturing industry.

Please do not consider this data as investment advice. Data is downloaded from sources we deem reliable, but errors may occur.

Company Info

Business Description

Company logo Intellia Therapeutics is a leading clinical-stage genome editing company, focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creating enhanced engineered cells that can treat oncological and immunological diseases. Intellia's combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts it in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create new classes of therapeutic products.

Identity

Sector and Industry

Share Data

Shares

Earnings and Dividends

Market Risk Measures

Many of the following risk metrics are standardized and transformed into quantitative factors in institutional-level risk models.

Rankings below represent percentiles from 1 to 100, with 1 being the lowest rating of risk.

Systematic Risk

Stocks with higher beta exhibit higher sensitivity to the ups and downs in the market. (↑↑)

Company Size

Stocks with higher market capitalization often have lower risk. (↑↓)

Trading Liquidity

Higher average daily dollar volume over the past 30 days implies lower liquidity risk. (↑↓)

Price Momentum

Higher price momentum stocks, aka recent winners, equate to lower risk for many investors. (↑↓)

Financial Risk Measures

Style risk factors often include measures of profitability and payout levels.

Earnings Yield

Companies with higher earnings generally provide lower risk. (↑↓)

Dividend Yield

Companies with higher dividend yields, if sustaintable, are perceived to have lower risk. (↑↓)

/ factorpad.com / stocks / f16qgj.html


NTLA stock risk
INTELLIA THERAPEUTICS INC stock beta
NTLA risk report
NTLA f16qgj
NTLA risk analysis
NTLA volatility
INTELLIA THERAPEUTICS INC credit risk
NTLA liquidity risk
NTLA leverage
NTLA valuation
NTLA systematic risk
NTLA specific risk
INTELLIA THERAPEUTICS INC volatility
NTLA analysis
NTLA financial ratio

A newly-updated free resource. Connect and refer a friend today.